Strategies for Understanding and Reducing the and Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model

1. World Health Organization. World malaria report 2014. Geneva: World Health Organization; 2014.

2. Cotter C, Sturrock H, Hsiang M, Liu J, Phillips A, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013;382:900–911. doi: 10.1016/S0140-6736(13)60310-4 23594387

3. Pan American Health Organization, World Health Organization. Central America and Hispaniola seek to eliminate malaria by 2025. 21 May 2013. Geneva: World Health Organization.

4. Asia Pacific Leaders Malaria Alliance. East Asia Summit adopts unprecedented regional malaria goal. 14 November 2014. Mandaluyong City (Philippines): Asia Pacific Leaders Malaria Alliance.

5. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009;9:555–566. doi: 10.1016/S1473-3099(09)70177-X 19695492

6. Baird JK. Eliminating malaria—all of them. Lancet. 2010;376:1883–1885. doi: 10.1016/S0140-6736(10)61494-8 21035840

7. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297. doi: 10.1186/1475-2875-10-297 21989376

8. Carson P, Flanagan C, Ickes C, Alving A. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956;124:484–485. 13360274

9. White NJ, Imwong M. Relapse. Adv Parasitol. 2012;80:113–150. doi: 10.1016/B978-0-12-397900-1.00002-5 23199487

10. Mckenzie FE, Jeffery GM, Collins WE. Plasmodium vivax blood-stage dynamics. J Parasitol. 2008;88:521–535.

11. Barry AE, Waltmann A, Koepfli C, Barnadas C, Mueller I. Uncovering the transmission dynamics of Plasmodium vivax using population genetics. Pathog Glob Health. 2015;109:142–152. doi: 10.1179/2047773215Y.0000000012 25891915

12. Liu Y, Auburn S, Cao J, Trimarsanto H, Zhou H, Gray K-A, et al. Genetic diversity and population structure of Plasmodium vivax in central China. Malar J. 2014;13:262. doi: 10.1186/1475-2875-13-262 25008859

13. Gray K-A, Dowd S, Bain L, Bobogare A, Wini L, Shanks GD, et al. Population genetics of Plasmodium falciparum and Plasmodium vivax and asymptomatic malaria in Temotu Province, Solomon Islands. Malar J. 2013;12:429. doi: 10.1186/1475-2875-12-429 24261646

14. Gunawardena S, Ferreira M, Kapilananda G, Wirth D, Karunaweera N. The Sri Lankan paradox: high genetic diversity in Plasmodium vivax populations despite decreasing levels of malaria transmission. Parasitology. 2014;141:880–890. doi: 10.1017/S0031182013002278 24533989

15. Lin JT, Saunders DL, Meshnick SR. The role of submicroscopic parasitemia in malaria transmission: what is the evidence ? Trends Parasitol. 2014;30:183–190. doi: 10.1016/j.pt.2014.02.004 24642035

16. malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 2011;8:e1000402. doi: 10.1371/journal.pmed.1000402 21311580

17. World Health Organization. Plasmodium vivax control & elimination: development of global strategy and investment case. Geneva: World Health Organization; 2012.

18. Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, Laumaea A, et al. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS ONE. 2010;5:e9047. doi: 10.1371/journal.pone.0009047 20140220

19. Senn N, Rarau P, Stanisic DI, Robinson L, Manong D, Salib M, et al. Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial. PLoS Med. 2012;9:e1001195. doi: 10.1371/journal.pmed.1001195 22479155

20. Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, Susapu M, et al. The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg. 2007;76:997–1008. 17556601

21. Kasehagen LJ, Mueller I, McNamara DT, Bockarie MJ, Kiniboro B, Rare L, et al. Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg. 2006;75:588–596. 17038678

22. Mueller I, Widmer S, Michel D, Maraga S, McNamara DT, Kiniboro B, et al. High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malar J. 2009;8:41. doi: 10.1186/1475-2875-8-41 19284594

23. Arnott A, Barnadas C, Senn N, Siba P, Mueller I, Reeder JC, et al. High genetic diversity of Plasmodium vivax on the north coast of Papua New Guinea. Am J Trop Med Hyg. 2013;89:188–194. doi: 10.4269/ajtmh.12-0774 23690553

24. Schultz L, Wapling J, Mueller I, Ntsuke PO, Senn N, Nale J, et al. Multilocus haplotypes reveal variable levels of diversity and population structure of Plasmodium falciparum in Papua New Guinea, a region of intense perennial transmission. Malar J. 2010;9:336. doi: 10.1186/1475-2875-9-336 21092231

25. Koepfli C, Robinson LJ, Rarau P, Salib M, Sambale N, Wampfler R et al. Blood-stage parasitaemia and age determine Plasmodium falciparum and P. vivax gametocytaemia in Papua New Guinea. PLoS ONE. 2015;10:e0126747. doi: 10.1371/journal.pone.0126747 25996916

26. Mueller I, Schoepflin S, Smith TA, Benton KL, Bretscher MT, Lin E, et al. Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A. 2012;109:10030–10035. doi: 10.1073/pnas.1200841109 22665809

27. Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1–5 years of age. J Infect Dis. 2012;206:1771–1780. doi: 10.1093/infdis/jis580 22966124

28. Hetzel M, Pulford J, Gouda H, Hodge A, Siba P, Mueller I. The Papua New Guinea National Malaria Control Program: primary outcome and impact indicators, 2009–2014. Goroka: Papua New Guinea Institute of Medical Research; 2014.

29. Mckenzie FE, Magill AJ, Forney JR, Lucas C, Erhart LM, Meara WPO, et al. Gametocytemia in Plasmodium vivax and Plasmodium falciparum infections. J Parasitol. 2006;92:1281–1285. 17304807

30. Douglas NM, Simpson JA, Phyo AP, Siswantoro H, Hasugian AR, Kenangalem E, et al. Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax. J Infect Dis. 2013;208:801–812. doi: 10.1093/infdis/jit261 23766527

31. Barbosa S, Gozze AB, Lima NF, Batista CL, Bastos MDS, Nicolete VC, et al. Epidemiology of disappearing Plasmodium vivax malaria: a case study in rural Amazonia. PLoS Negl Trop Dis. 2014;8:e3109. doi: 10.1371/journal.pntd.0003109 25166263

32. Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ, et al. The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS ONE. 2011;6:e20179. doi: 10.1371/journal.pone.0020179 21629651

33. Grueninger H, Hamed K. Transitioning from malaria control to elimination: the vital role of ACTs. Trends Parasitol. 2013;29:60–64. doi: 10.1016/j.pt.2012.11.002 23228225

34. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049–1058. doi: 10.1016/S0140-6736(13)62568-4 24360369

35. Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, et al. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult Thai subjects. Antimicrob Agents Chemother. 2014;58:7340–7346. doi: 10.1128/AAC.03704-14 25267661

36. Genton B, D’Acremont VV, Rare L, Baea K, Reeder JC, Alpers MP, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children : a prospective cohort study from Papua New Guinea. PLoS Med. 2008;5:e127. doi: 10.1371/journal.pmed.0050127 18563961

37. Betuela I, Bassat Q, Kiniboro B, Robinson LJ, Rosanas-Urgell A, Stanisic D, et al. Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age. Antimicrob Agents Chemother. 2012;56:2146–2149. doi: 10.1128/aac.05566-11 22252800

38. Laman M, Laman M, Moore BR, Benjamin J, Padapu N, Tarongka N, et al. Comparison of an assumed versus measured leucocyte count in parasite density calculations in Papua New Guinean children with uncomplicated malaria. Malar J. 2014;13:145. doi: 10.1186/1475-2875-13-145 24739250

39. Wampfler R, Mwingira F, Javati S, Robinson L, Betuela I, Siba P, et al. Strategies for detection of Plasmodium species gametocytes. PLoS ONE. 2013;8:e76316. doi: 10.1371/journal.pone.0076316 24312682

40. Rosanas-Urgell A, Mueller D, Betuela I, Barnadas C, Iga J, Zimmerman PA, et al. Comparison of diagnostic methods for the detection and quantification of the four sympatric Plasmodium species in field samples from Papua New Guinea. Malar J. 2010;9:361. doi: 10.1186/1475-2875-9-361 21156052

41. Koepfli C, Schoepflin S, Bretscher M, Lin E, Kiniboro B, Zimmerman PA, et al. How much remains undetected? Probability of molecular detection of human Plasmodia in the field. PLoS ONE. 2011;6:e19010. doi: 10.1371/journal.pone.0019010 21552561

42. Koepfli C, Colborn KL, Kiniboro B, Lin E, Speed TP, Siba PM, et al. A high force of Plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in Papua New Guinean children. PLoS Negl Trop Dis. 2013;7:e2403. doi: 10.1371/journal.pntd.0002403 24040428

43. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Found Statistical Computing; 2014.

44. StataCorp. Stata release 12 [computer program]. College Station (Texas): StataCorp; 2011.

45. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med. 2008;359:2545–2557. doi: 10.1056/NEJMoa0804915 19064624

46. Smith D, McKenzie F. Statics and dynamics of malaria infection in Anopheles mosquitoes. Malar J. 2004;3:13. 15180900

47. Smith DL, Battle KE, Hay SI, Barker CM, Scott TW, McKenzie FE. Ross, Macdonald, and a theory for the dynamics and control of mosquito-transmitted pathogens. PLoS Pathog. 2012;8:e1002588. doi: 10.1371/journal.ppat.1002588 22496640

48. White MT, Karl S, Battle KE, Hay SI. Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission. Elife. 2014;3:1–19. doi: 10.7554/eLife.04692

49. Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Li Wai Suen CSN, et al. Data from: Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: A randomised placebo-controlled trial and mathematical model. Dryad Digital Repository.

50. Coleman R, Kumpitak C, Ponlawat A, Maneechai N, Phunkitchar V, Rachapaew N, et al. Infectivity of asymptomatic Plasmodium-infected human populations to Anopheles dirus mosquitoes in western Thailand. J Med Entomol. 2004;41:201–208. 15061279

51. Sattabongkot J, Maneechai N, Rosenberg R. Plasmodium vivax: gametocyte infectivity of naturally infected Thai adults. Parasitology. 1991;102:27–31. 2038501

52. Bharti AR, Chuquiyauri R, Brouwer KC, Stancil J, Lin J, Llanos-cuentas A, et al. Experimental infection of the neotropical malaria vector Anopheles darlingi by human patient-derived Plasmodium vivax in the Peruvian Amazon. Am J Trop Med Hyg. 2007;75:610–616.

53. Imwong M, Boel ME, Pagornrat W, Pimanpanarak M, McGready R, Day NPJ, et al. The first Plasmodium vivax relapses of life are usually genetically homologous. J Infect Dis. 2012;205:680–683. doi: 10.1093/infdis/jir806 22194628

54. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis. 2007;195:934–941. doi: 10.1086/512242 17330782

55. Bright AT, Manary MJ, Tewhey R, Arango EM, Wang T, Schork NJ, et al. A high resolution case study of a patient with recurrent Plasmodium vivax infections shows that relapses were caused by meiotic siblings. PLoS Negl Trop Dis. 2014;8:e2882. doi: 10.1371/journal.pntd.0002882 24901334

56. Mueller I, Zimmerman PA, Reeder JC. Plasmodium malariae and Plasmodium ovale—the “bashful” malaria parasites. Trends Parasitol. 2007;23:278–283. doi: 10.1016/j.pt.2007.04.009 17459775

57. White NJ. Malaria. In: Cook GC, Zumla AI, editors. Manson’s tropical diseases. 21st ed. Philadelphia: W. B. Saunders; 2003. pp. 1205–1296.

58. Siala E, Khalfaoui M, Bouratbine A, Hamdi S, Hili K, Aoun K. Relapse of Plasmodium malariae malaria 20 years after living in an endemic area. Presse Med. 2005;34:371–372. 15859572

59. Laman M, Moore BR, Benjamin JM, Yadi G, Bona C, Warrel J, et al. Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial. PLoS Med. 2014;11:e1001773. doi: 10.1371/journal.pmed.1001773 25549086

60. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis. 2011;52:612–620. doi: 10.1093/cid/ciq249 21292666

61. Karl S, Laman M, Koleala T, Ibam C, Kasian B, Drewei NN, et al. Comparison of three methods for detection of gametocytes in Melanesian children treated for uncomplicated malaria. Malar J. 2014;13:1–8. doi: 10.1186/1475-2875-13-319

62. Okell LC, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun. 2012;3:1237. doi: 10.1038/ncomms2241 23212366

63. Schneider P, Bousema J, Gouagna L, Otieno S, van de Vegte-Bolmer M, Omar S, et al. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg. 2007;76:470–474. 17360869

64. Ouédraogo AL, Bousema T, Schneider P, de Vlas SJ, Ilboudo-Sanogo E, Cuzin-Ouattara N, et al. Substantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS ONE. 2009;4:e8410. doi: 10.1371/journal.pone.0008410 20027314

65. Koch R. Professor Koch’s investigations on malaria: fourth report to the Colonial Department of the German Colonial Office. Br Med J. 1900;1:1597–1598. 20759083

66. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med. 2010;7:e1000324. doi: 10.1371/journal.pmed.1000324 20711482

67. Crowell V, Briët OJT, Hardy D, Chitnis N, Maire N, Di Pasquale A, et al. Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden. Malar J. 2013;12:4. doi: 10.1186/1475-2875-12-4 23286228

68. Tiono AB, Ouédraogo A, Ogutu B, Diarra A, Coulibaly S, Gansané A, et al. A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso. Malar J. 2013;12:79. doi: 10.1186/1475-2875-12-79 23442748

69. Tiono AB, Ouédraogo A, Diarra A, Coulibaly S, Soulama I, Konaté AT, et al. Lessons learned from the use of HRP-2 based rapid diagnostic test in community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso. Malar J. 2014;13:30. doi: 10.1186/1475-2875-13-30 24467946

70. Halliday KE, Okello G, Turner EL, Njagi K, Mcharo C, Kengo J, et al. Impact of intermittent screening and treatment for malaria among school children in Kenya: a cluster randomised trial. PLoS Med. 2014;11:e1001594. doi: 10.1371/journal.pmed.1001594 24492859

71. Mosha JF, Sturrock HJW, Greenhouse B, Greenwood B, Sutherland CJ, Gadalla N, et al. Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics. Malar J. 2013;12:221. doi: 10.1186/1475-2875-12-221 23815811

72. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39:1336–1345. doi: 10.1086/424663 15494911

73. Beutler E. G6PD deficiency. Blood. 1994;84:3613–3636. 7949118

74. Kondrashin A, Baranova AM, Ashley EA, Recht J, White NJ, Sergiev VP. Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malar J. 2014;13:51. doi: 10.1186/1475-2875-13-51 24502194

75. Von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112. doi: 10.1186/1475-2875-12-112 23537118

76. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, et al. Performance of the CareStartTM G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS ONE. 2011;6:e28357. doi: 10.1371/journal.pone.0028357 22164279

77. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13:144. doi: 10.1186/1475-2875-13-144 24731298